The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Leukemia

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/leu.2008.238PMID 18769446
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells.

  2007cited by this paper
• Overexpression of CXCR4 predicts adverse overall and event‐free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype

  2007cited by this paper
• CXCR4 is a prognostic marker in acute myelogenous leukemia.

  2007cited by this paper
• Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias

  2006cited by this paper
• Targeting of CD44 eradicates human acute myeloid leukemic stem cells

  2006cited by this paper
• Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches.

  2006cited by this paper
• Motility, proliferation, and egress to the circulation of human AML cells are elastase dependent in NOD/SCID chimeric mice.

  2005cited by this paper
• Leukaemia stem cells and the evolution of cancer-stem-cell research

  2005cited by this paper
• CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice.

  2004cited by this paper
• Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia.

  2004cited by this paper
• The transcriptional program of terminal granulocytic differentiation.

  2004cited by this paper
• A highly sensitive strategy for SCID-repopulating cell assay by direct injection of primitive human hematopoietic cells into NOD/SCID mice bone marrow.

  2003cited by this paper
• Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia

  2003cited by this paper
• Hematopoietic Stem Cells Are Uniquely Selective in Their Migratory Response to Chemokines

  2002cited by this paper
• Stromal cell-derived factor 1 regulates primitive hematopoiesis by suppressing apoptosis and by promoting G(0)/G(1) transition in CD34(+) cells: evidence for an autocrine/paracrine mechanism.

  2002cited by this paper
• Effects of anti-CD44 monoclonal antibodies on differentiation and apoptosis of human myeloid leukemia cell lines.

  2002cited by this paper
• Enhancement of intracellular signaling associated with hematopoietic progenitor cell survival in response to SDF-1/CXCL12 in synergy with other cytokines.

  2002cited by this paper
• Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5).

  2001cited by this paper
• Rapid and efficient homing of human CD34(+)CD38(-/low)CXCR4(+) stem and progenitor cells to the bone marrow and spleen of NOD/SCID and NOD/SCID/B2m(null) mice.

  2001cited by this paper
• Functional response of leukaemic blasts to stromal cell‐derived factor‐1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia

  2000cited by this paper
• Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4.

  1999cited by this paper
• Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice.

  1999cited by this paper
• Ligation of the CD44 adhesion molecule reverses blockage of differentiation in human acute myeloid leukemia

  1999cited by this paper
• Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties.

  1998cited by this paper
• The Chemokine SDF-1 Is a Chemoattractant for Human CD34+ Hematopoietic Progenitor Cells and Provides a New Mechanism to Explain the Mobilization of CD34+ Progenitors to Peripheral Blood

  1997cited by this paper
• All-trans retinoic acid rapidly decreases cathepsin G synthesis and mRNA expression in acute promyelocytic leukemia.

  1996cited by this paper
• Granulocyte colony-stimulating factor induction of normal human bone marrow progenitors results in neutrophil-specific gene expression.

  1995cited by this paper
• Biosynthesis of granule proteins in normal human bone marrow cells. Gelatinase is a marker of terminal neutrophil differentiation.

  1995cited by this paper
• Interaction of acute leukemia cells with the bone marrow microenvironment: implications for control of minimal residual disease.

  1995cited by this paper
• A cell initiating human acute myeloid leukaemia after transplantation into SCID mice

  1994cited by this paper
• Regulation of myeloblastin messenger RNA expression in myeloid leukemia cells treated with all-trans retinoic acid.

  1993cited by this paper
• Stimulation of leukemic myelopoiesis by P30-35 CAMAL, an inhibitor of normal myelopoiesis.

  1993cited by this paper
• Three human elastase-like genes coordinately expressed in the myelomonocyte lineage are organized as a single genetic locus on 19pter.

  1992cited by this paper
• Purification of an in vitro inhibitor of normal myelopoiesis using a monoclonal antibody directed to a common antigen of myelogenous leukemia (CAMAL).

  1991cited by this paper
• Down-regulation of a serine protease, myeloblastin, causes growth arrest and differentiation of promyelocytic leukemia cells.

  1989cited by this paper

• CD73: a new immune checkpoint for leukemia treatment

  2025cites this paper
• New perspectives on chemokines in hepatocellular carcinoma therapy: a critical pathway for natural products regulation of the tumor microenvironment

  2024cites this paper
• In vitro effects and mathematical modelling of CTCE‐9908 (a chemokine receptor 4 antagonist) on melanoma cell survival

  2024cites this paper
• Self-Stimulated Photodynamic Nanoreactor in Combination with CXCR4 Antagonists for Antileukemia Therapy.

  2024cites this paper
• CXCR4 as a therapeutic target in acute myeloid leukemia

  2024influential citation
• Clinical Aspects and Significance of β-Chemokines, γ-Chemokines, and δ-Chemokines in Molecular Cancer Processes in Acute Myeloid Leukemia (AML) and Myelodysplastic Neoplasms (MDS)

  2024cites this paper
• CXCL12/CXCR4 Axis Promotes the Chemotaxis and Phagocytosis of B Cells through the PI3K-AKT Signaling Pathway in an Early Vertebrate.

  2024cites this paper
• Bone marrow stromal cells reduce low-dose cytarabine-induced differentiation of acute myeloid leukemia

  2023cites this paper
• Study on the mechanism of CXCL12/CXCR4-axis-mediated upregulation of IL-8 and IL-6 on the biological function of acute T lymphocyte leukaemia cells

  2023cites this paper
• Characteristics of leukemic stem cells in acute leukemia and potential targeted therapies for their specific eradication

  2022cites this paper
• Cimigenol depresses acute myeloid leukemia cells protected by breaking bone marrow stromal cells via CXCR4/SDF‑1α

  2022influential citation
• Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS.

  2021cites this paper
• A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes

  2021cites this paper
• Role of CXCR4 in the progression and therapy of acute leukaemia

  2021cites this paper
• A multivalent Ara-C-prodrug nanoconjugate achieves selective ablation of leukemic cells in an acute myeloid leukemia mouse model.

  2021cites this paper
• Leukaemia: a model metastatic disease

  2021cites this paper
• Synthetic CXCR4 Antagonistic Peptide Assembling with Nanoscaled Micelles Combat Acute Myeloid Leukemia.

  2020cites this paper
• CXCR4 Signaling Has a CXCL12-Independent Essential Role in Murine MLL-AF9-Driven Acute Myeloid Leukemia

  2020cites this paper
• CXCR4 Inhibition Enhances Efficacy of FLT3 Inhibitors in FLT3-Mutated AML Augmented by Suppressed TGF-β Signaling

  2020cites this paper
• Nile tilapia CXCR4, the receptor of chemokine CXCL12, is involved in host defense against bacterial infection and chemotactic activity.

  2020cites this paper
• Subcutaneous Administration of AMD3100 into Mice Models of Alzheimer’s Disease Ameliorated Cognitive Impairment, Reduced Neuroinflammation, and Improved Pathophysiological Markers

  2020cites this paper
• Prognostic significance of CXCR4 expression in acute myeloid leukemia

  2019cites this paper
• Not Only Mutations Matter: Molecular Picture of Acute Myeloid Leukemia Emerging from Transcriptome Studies

  2019cites this paper
• MiR-9 functions as a tumor suppressor in acute myeloid leukemia by targeting CX chemokine receptor 4.

  2019cites this paper
• Adhesion Deregulation in Acute Myeloid Leukaemia

  2019cites this paper
• Tissue-Nonspecific Alkaline Phosphatase Is Required for MC3T3 Osteoblast–Mediated Protection of Acute Myeloid Leukemia Cells from Apoptosis

  2018cites this paper
• Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies.

  2018cites this paper
• New therapeutic opportunities from dissecting the pre-B leukemia bone marrow microenvironment

  2018cites this paper
• The good and bad faces of the CXCR4 chemokine receptor.

  2018cites this paper
• Therapeutic Antibodies for Myeloid Neoplasms—Current Developments and Future Directions

  2018cites this paper
• TGF-β1 and CXCL12 modulate proliferation and chemotherapy sensitivity of acute myeloid leukemia cells co-cultured with multipotent mesenchymal stromal cells

  2018cites this paper
• Mesenchymal Stem Cells Support Survival and Proliferation of Primary Human Acute Myeloid Leukemia Cells through Heterogeneous Molecular Mechanisms

  2017cites this paper
• Targeting the CXCL12/CXCR4 axis in acute myeloid leukemia: from bench to bedside

  2017cites this paper
• A phase 1 study of the CXCR4 antagonist plerixafor in combination with high‐dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators’ Consortium study (POE 10‐03)

  2017cites this paper
• Understanding the bone marrow microenvironment in hematologic malignancies: A focus on chemokine, integrin, and extracellular vesicle signaling

  2017cites this paper
• Development of Diagnostic and Therapeutic Radiopharmaceuticals targeting the Chemokine Receptor 4

  2017cites this paper
• The Tumor Microenvironment as Therapeutic Target in Pediatric Acute Leukemia

  2017cites this paper
• Bruton’s tyrosine kinase and RAC1 promote cell survival in MLL-rearranged acute myeloid leukemia

  2017cites this paper
• The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression

  2017cites this paper
• Tumor Trp53 status and genotype affect the bone marrow microenvironment in acute myeloid leukemia

  2017cites this paper
• The CCL2/CCR2 Axis Affects Transmigration and Proliferation but Not Resistance to Chemotherapy of Acute Myeloid Leukemia Cells

  2017cites this paper
• Targeting the leukemia–stroma interaction in acute myeloid leukemia: rationale and latest evidence

  2016cites this paper
• Granulocyte colony-stimulating factor inhibits CXCR4/SDF-1α signaling and overcomes stromal-mediated drug resistance in the HL-60 cell line.

  2016cites this paper
• Tetraspanin 3 Is Required for the Development and Propagation of Acute Myelogenous Leukemia.

  2015cites this paper
• POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALL

  2015cites this paper
• Bone Marrow Microenvironment-mediated Resistance to Chemotherapy in Leukemia

  2015cites this paper
• Targeting the Microenvironment in Acute Myeloid Leukemia

  2015cites this paper
• Performance status in elderly patients with acute myeloid leukemia: exploring gene expression signatures of cytokines and chemokines.

  2015cites this paper
• Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy.

  2015cites this paper
• Plerixafor: potential role in acute leukemia therapy

  2015cites this paper
• A hostel for the hostile: the bone marrow niche in hematologic neoplasms

  2015cites this paper
• CXCR4/CXCL12 as a Therapeutic Target

  2015cites this paper
• [CXCR4: a new therapeutic target of the leukaemic cell? Role of the SDF-1/CXCR4 axis in acute myeloid leukaemia].

  2014cites this paper
• CXCR4 Expression, CXCR4 Activation, and Wild Type NPM1 Are Independently Associated with Unfavorable Prognosis in Patients with Acute Myeloid Leukemia

  2014cites this paper
• An Overview of Acute Myeloid Leukemia and Cancer Immunology: (i) Concepts and Therapeutic Strategies and (ii) RepSox as a Candidate Cell-Engineering Tool

  2014cites this paper
• Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patients

  2014cites this paper
• Modulation of Selectin-Mediated Adhesion of Flowing Lymphoma and Bone Marrow Cells by Immobilized SDF-1

  2014influential citation
• Targeting the Molecular and Cellular Interactions of the Bone Marrow Niche in Immunologic Disease

  2014cites this paper
• Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition

  2014cites this paper
• CXC Chemokine Ligand 12 Protects Pancreatic β-Cells from Necrosis through Akt Kinase-Mediated Modulation of Poly(ADP-ribose) Polymerase-1 Activity

  2014influential citation
• RepSox Slows Decay of CD34+ Acute Myeloid Leukemia Cells and Decreases T Cell Immunoglobulin Mucin‐3 Expression

  2014cites this paper
• CXC chemokine receptor 4 expression, CXC chemokine receptor 4 activation, and wild-type nucleophosmin are independently associated with unfavorable prognosis in patients with acute myeloid leukemia.

  2013cites this paper
• The Bone Marrow Microenvironment: Novel Targets to Circumvent Minimal Residual Disease and Drug Resistance in Multiple Myeloma

  2013cites this paper
• Cell Death and Survival Dynamic Chemotherapy-Induced Upregulation of CXCR 4 Expression : A Mechanism of Therapeutic Resistance in Pediatric AML

  2013cites this paper
• CXCR7 impact on CXCL12 biology and disease.

  2013cites this paper
• Dynamic Chemotherapy-Induced Upregulation of CXCR4 Expression: A Mechanism of Therapeutic Resistance in Pediatric AML

  2013cites this paper
• Endogenous stromal cell-derived factor-1 (CXCL12) supports autonomous growth of acute myeloid leukemia cells.

  2013cites this paper
• Role of CXCR4 in the Pathogenesis of Acute Myeloid Leukemia

  2013cites this paper
• Advances in Biology and Therapy of Multiple Myeloma

  2013cites this paper
• MLL‐rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism

  2013influential citation
• Clonal selection and therapy resistance in acute leukaemias: mathematical modelling explains different proliferation patterns at diagnosis and relapse

  2013cites this paper
• Dynamic Chemotherapy-Induced Upregulation of CXCR4 Expression: A Mechanism of Therapeutic Resistance in

  2013cites this paper
• Interleukin-27 Inhibits the Growth of Pediatric Acute Myeloid Leukemia in NOD/SCID/Il2rg−/− Mice

  2012cites this paper
• Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML.

  2012cites this paper
• The Regulation of Normal and Leukemic Hematopoietic Stem Cells by Niches

  2012cites this paper
• The mesenchymal tumor microenvironment

  2012cites this paper
• Pharmacogenomic considerations of xenograft mouse models of acute leukemia.

  2012cites this paper
• CXCR4 Antagonists for the Treatment of CML

  2012cites this paper
• Preclinical Experience with AMD3100 for Mobilization of Hematopoietic Stem and Progenitor Cells

  2012cites this paper
• murine model of CML Effects of plerixafor in combination with BCR-ABL kinase inhibition in a

  2012cites this paper
• Cellular trafficking in haematological and immunological disorders

  2012cites this paper
• Get out--and stay out.

  2012cites this paper
• Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist

  2011cites this paper
• CXCR4 as a Therapeutic Target

  2011cites this paper
• MicroRNA-146a and AMD3100, two ways to control CXCR4 expression in acute myeloid leukemias

  2011cites this paper
• CXCR4 antagonists in hematologic malignancies: more than just mobilizers?

  2011cites this paper
• Identification and Regulation of c-Myb Target Genes in MCF-7 Cells

  2011cites this paper
• Identification of Single- and Multiple-Class Specific Signature Genes from Gene Expression Profiles by Group Marker Index

  2011cites this paper
• Differential effects of CXCR4 antagonists on the survival and proliferation of myeloid leukemia cells in vitro

  2011influential citation
• The Use of Mouse Models to Study Leukemia/Lymphoma and Assess Therapeutic Approaches

  2011cites this paper
• The bone marrow microenvironment and leukemia: biology and therapeutic targeting

  2011cites this paper
• Nuevas estrategias terapéuticas en leucemias agudas mieloblásticas: evaluación preclínica de la eficacia y el mecanismo de ación

  2011cites this paper
• Can inhibition of the SDF-1/CXCR4 axis eradicate acute leukemia?

  2010cites this paper
• Valproic acid exerts differential effects on CXCR4 expression in leukemic cells.

  2010cites this paper
• The CXCR4 Antagonist AMD3100 Has Dual Effects on Survival and Proliferation of Myeloma Cells In Vitro

  2010cites this paper
• Targeting the acute myeloid leukemia stem cells.

  2010cites this paper
• The chemokine network in acute myelogenous leukemia: molecular mechanisms involved in leukemogenesis and therapeutic implications.

  2010cites this paper
• Impact of CXCR4 inhibition on FLT3-ITD-positive human AML blasts.

  2010cites this paper
• Chemokine/chemokine receptor interactions in extramedullary leukaemia of the skin in childhood AML: Differential roles for CCR2, CCR5, CXCR4 and CXCR7

  2010cites this paper
• Role of I-TAC-binding receptors CXCR3 and CXCR7 in proliferation, activation of intracellular signaling pathways and migration of various tumor cell lines.

  2010cites this paper